Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up ...

Eli Lilly (LLY) on Monday announced an agreement to acquire Kelonia Therapeutics, a privately held cancer drug developer, in a deal worth up to $7B in cash, confirming a prior report from The Wall ...

Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene therapy maker Kelonia Therapeutics for at least $3.25 billion, the companies announced Monday. The acquisition will grant ...

Eli Lilly’s LLY3.07%increase; green up pointing triangle late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. Achieve-4, the longest phase 3 ...

Eli Lilly's acquisition spree shows no sign of stalling, although the Big Pharma is keeping the terms of its latest buy pretty vague. This time, Lilly has returned to antibody-drug conjugates (ADCs), ...

Eli Lilly (LLY) reported Q4 revenue of $19.29B up 42.6% YoY, with Mounjaro generating $7.41B (up 110%) and Zepbound adding $4.26B (up 123%). Novo Nordisk (NVO) posted Q4 revenue down 7.6% YoY and cut ...

The FDA approved a GLP-1 pill from Eli Lilly called Foundayo. Foundayo isn't as effective as Lilly's weekly shot Zepbound, but the once-daily pill could be attractive for people looking for ...

Eli Lilly and Co. is spending as much as $1.8 billion to upgrade its near-downtown Indianapolis research and manufacturing operations over the next several years. The investment, shared with IBJ this ...

Eli Lilly (LLY) shares slipped in the premarket on Tuesday after HSBC downgraded the weight loss drugmaker to Reduce from Hold, issuing the pharma giant’s only sell-equivalent rating on Wall Street, ...

Roseanne Barr is opening up about the dynamics behind the scenes of her hit sitcom "Roseanne." During a recent episode of "The Roseanne Barr Podcast," the 73-year-old comedian spoke with Michael ...

Eli Lilly stock is down 13% from its 52-week high. Analysts still see some decent upside for the stock, with its average price target being north of $1,200. The company experienced tremendous growth ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...